Amphista Therapeutics is the leading European targeted protein degradation (TPD) company.
We have developed several completely novel mechanisms to remove disease-causing proteins with the potential to overcome many of the limitations seen with current TPD approaches. Our therapeutics, known as Amphistas, have the potential to deliver transformational medicines to treat a wide range of diseases.
- Amphista Therapeutics Appoints CBO, Beverley Carr 1 November 2021
- Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm 21 September 2021
At Amphista, we are building a better future by creating an exciting and fast-moving working environment that fosters opportunity. Come and join our team and help us make a difference.